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Table 1. Definition of a massive transfusion. Adapted from Pham and Shaz 2013. 
Definition of a Massive Transfusion 
1. Transfusion of  ≥ 10 red blood cell (RBC) units (roughly the total blood volume of an 
average adult) within 24 hours 
2. Transfusion of > 4 RBC units in 1 hour and an expected need for a continued blood 
product support, and 
3. Restoring > 50 % of TBV with blood products within 3 hours 




Table 2. The scoring system used to trigger the massive transfusion (MT) protocol. Two of the 
four markers must be positive for the initiation of the MT protocol. Adapted from Nunez et al. 
2009. 
Massive Transfusion Triggering Protocol 
Penetrating trauma 
Systolic arterial pressure < 90 mmHg 
Heart rate > 120 /min 
Positive FAST 


























































Table 3. ROTEM® variables with their respective reference ranges (II-III). 
Variables  Reference Range 
Clotting time (CT) s EXTEM: 38-79, INTEM: 100-240 
Clot formation time (CFT) s EXTEM: 34-159, INTEM: 30-110 
Maximum clot firmness (MCF) mm EXTEM and INTEM: 50-72, FIBTEM: 9-25  














Table 4. Thrombin generation characteristics in SD plasma compared to pooled reference 
plasma from Sanquin in CAT®. Difference between SD plasmas and reference plasma 
calculated as fold with p-values to show statistical difference. Number of plasma batches used: 
Octaplas® n = 2, Omniplasma® n = 3.  
Plasma Lag time ETP Peak TG 
 fold p fold p fold p 
Octaplas® -1.5 0.003 2 0.003 4 0.002 
Omniplasma® -1.2 0.009 2 0.0003 4 0.00003 









Table 5. Levels of the inhibitors of thrombin generation (TG), fibrinolysis markers and lipids 
in Octaplas®, Omniplasma® and the reference plasma (ref. plasma) obtained from healthy 
volunteers. Data are presented as mean ±  standard deviation. Number of plasma batches used, 
please see Table 4. 








TG inhibitors      
AT  % 80-120 97±3 83±3∗ 90±3 
PC % 75-125 111±13 96±0 100±2 
PS total ag % 60-140 98±6 66±2∗∗ 86±5 
PS free ag % 60-140 95±4 68±3∗∗ 82±1∗  
PS intact ag % of total ag  65±0 14±0∗∗∗ 12.5±0.5∗∗∗ 
 























      
Fibrinolysis markers      
Plasminogen % 80-120 110±11 91±0 88±1 
α2-AP % 80-120 114±20 23±3∗ 43±4∗ 
      
Lipids♣      
HDL mmol/L w > 1.2 
m > 1.0 
1.3±0.1 1.5±0.01 1.6±0.01 
LDL mmol/L < 3 2.3±0.2 0.2±0.01∗∗∗ 0.2±0.02∗∗∗ 
VLDL mmol/L  0.50±0.06 0.003±0∗∗∗ 0.005±0∗∗ 
α2-AP = α2-antiplasmin; AT = antithrombin; HDL = high-density lipoprotein; LDL = low-density 
lipoprotein; PC = protein C; PS = protein S; ag = antigen; TFPI = tissue factor pathway inhibitor; VLDL 
= very low-density lipoprotein; w = women; m = men ♣ = Unpublished data by Pitkänen et al 2018               



























Table 6. Major fibrinolysis regulators and clot lysis time (CLT) as derived from the optical 
density experiment in LPI and healthy controls. Data are presented as a median and range.  
Fibrinolysis regulators 
and markers 
 Controls LPI patients 
Plasminogen % 99 (92-111) 120 (91-155) ∗ 
α2-antiplasmin % 101 (95-113) 88 (50-105) ∗∗ 
Pls/α2-AP ratio  0.96 (0.82-1.16) 1.50 (1.10-2.02) ∗∗ 
CLT min 42 (31-91) 30 (24-49) ∗∗ 


















Table 7. Lipid values among LPI patients. LDL was obtained from 12 patients. Data are 
presented as a median and range. 
Lipids  Normal range LPI patients 
Total cholesterol mM < 5  5.8 (3.8-8.6) 
LDL mM < 3  3.5 (2.0-4.4) 
HDL mM w> 1.2 / m> 1.0 w: 1.2 (1.1-1.4) / m: 1.1 (0.5-1.3) 
Triglycerides mM < 2  2.6 (0.9-7.1) 
HDL = high-density lipoprotein; LDL = low-density lipoprotein; w = women; m = men 
 52 
Table 8. Renal and metabolic markers in LPI patients. 12 patients had low estimated 
glomerular filtration rate (eGFR), while cystatin C was elevated in 10 patients. Capillary blood 
gas analysis was obtained from 13 patients; 10/13 patients had low bicarbonate levels and 
base excess levels. Data are presented as a median and range. 





eGFR mL/min/m2 ∗ 44 (16-105) 
Cystatin C (serum) mg/L 0.6-1.1 1.4 (0.6-2.5) 
Lysine (urine) μmol/mmol Crea 2-63 406 (112-1076) 
Bicarbonate (whole blood) mM 22-26 21 (13-23) 
Base excess (whole blood) mM -2.5 to +2.5 -4.2 (-10.5 to -1.3) 
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